Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction

被引：2

作者：

Buller, Dylan M. ^{[1
]}

Antony, Maria ^{[2
]}

Ristau, Benjamin T. ^{[1
,3
]}

机构：

[1] UConn Hlth, Div Urol, Farmington, CT USA

[2] Univ Connecticut, Sch Med, Farmington, CT USA

[3] UConn Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA

来源：

ONCOTARGETS AND THERAPY | 2023年 / 16卷

关键词：

renal cell carcinoma; adjuvant therapy; targeted therapy; immunotherapy; radiation; PRIMARY KIDNEY CANCER; EARLY BREAST-CANCER; PHASE-III TRIAL; STEREOTACTIC ABLATIVE RADIOTHERAPY; POSTOPERATIVE PROGNOSTIC NOMOGRAM; RADIOSURGERY ONCOLOGY CONSORTIUM; BODY RADIOTHERAPY; OPEN-LABEL; INTERFERON-ALPHA; RANDOMIZED-TRIAL;

D O I：

10.2147/OTT.S393296

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Locally and regionally advanced renal cell carcinoma (RCC) can recur at high rates even after visually complete resection of primary disease. Both targeted therapies and immunotherapies represent potential agents that might help reduce recurrence of RCC in these patients. This paper reviews the current body of evidence defining their potential impact and examines the large Phase III randomized clinical trials that have been performed to assess the safety and efficacy of these systemic therapies in the adjuvant setting. Given that the findings from these trials have been predominantly negative, this paper also explores the role of other potential adjuvant agents, including single and combination agent targeted therapies and immunotherapies, whose use is currently limited to metastatic RCC. Finally, the use of radiation therapy and the use of advanced imaging modalities in RCC are also considered.

引用

页码：49 / 64

页数：16

共 152 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial [J].

Allaf, M. ;

Kim, S. E. ;

Harshman, L. C. ;

McDermott, D. F. ;

Master, V. A. ;

Signoretti, S. ;

Cole, S. ;

Moon, H. ;

Adra, N. ;

Singer, E. A. ;

Gills, J. ;

Choueiri, T. K. ;

Leibovich, B. ;

Michaelson, M. D. ;

Shuch, B. ;

Lara, P. N. ;

Heng, D. Y. C. ;

Kapoor, A. ;

Carducci, M. A. ;

Haas, N. B. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S1432-S1433

[3] Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma [J].

Amzal, Billy ;

Fu, Shuai ;

Meng, Jie ;

Lister, Johanna ;

Karcher, Helene .

PLOS ONE, 2017, 12 (09)

[4] Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses [J].

Andrews, Jack R. ;

Atwell, Thomas ;

Schmit, Grant ;

Lohse, Christine M. ;

Kurup, A. Nicholas ;

Weisbrod, Adam ;

Callstrom, Matthew R. ;

Cheville, John C. ;

Boorjian, Stephen A. ;

Leibovich, Bradley C. ;

Thompson, R. Houston .

EUROPEAN UROLOGY, 2019, 76 (02) :244-251

[5] The oral HIF-2 [alpha] inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. [J].

Bauer, Todd Michael ;

Choueiri, Toni K. ;

Papadopoulos, Kyriakos P. ;

Plimack, Elizabeth R. ;

Merchan, Jaime R. ;

McDermott, David F. ;

Michaelson, Dror M. ;

Appleman, Leonard Joseph ;

Thamake, Sanjay ;

Perini, Rodolfo F. ;

Park, Eric Kristopher ;

Jonasch, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[6] Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) [J].

Blum, Joanne L. ;

Flynn, Patrick J. ;

Yothers, Greg ;

Asmar, Lina ;

Geyer, Charles E., Jr. ;

Jacobs, Samuel A. ;

Robert, Nicholas J. ;

Hopkins, Judith O. ;

O'Shaughnessy, Joyce A. ;

Dang, Chau T. ;

Gomez, Henry Leonidas ;

Fehrenbacher, Louis ;

Vukelja, Svetislava J. ;

Lyss, Alan P. ;

Paul, Devchand ;

Brufsky, Adam M. ;

Jeong, Jong-Hyeon ;

Colangelo, Linda H. ;

Swain, Sandra M. ;

Mamounas, Eleftherios P. ;

Jones, Stephen E. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (23) :2647-+

[7] The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma [J].

Borregales, Leonardo D. ;

Adibi, Mehrad ;

Thomas, Arun Z. ;

Wood, Christopher G. ;

Karam, Jose A. .

THERAPEUTIC ADVANCES IN UROLOGY, 2016, 8 (02) :130-141

[8] PET imaging of immune checkpoint proteins in oncology [J].

Bouleau, Alizee ;

Lebon, Vincent ;

Truillet, Charles .

PHARMACOLOGY & THERAPEUTICS, 2021, 222

[9] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial [J].

Cameron, David ;

Piccart-Gebhart, Martine J. ;

Gelber, Richard D. ;

Procter, Marion ;

Goldhirsch, Aron ;

de Azambuja, Evandro ;

Castro, Gilberto, Jr. ;

Untch, Michael ;

Smith, Ian ;

Gianni, Luca ;

Baselga, Jose ;

Al-Sakaff, Nedal ;

Lauer, Sabine ;

McFadden, Eleanor ;

Leyland-Jones, Brian ;

Bell, Richard ;

Dowsett, Mitch ;

Jackisch, Christian .

LANCET, 2017, 389 (10075) :1195-1205

[10] Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma The ARISER Randomized Clinical Trial [J].

Chamie, Karim ;

Donin, Nicholas M. ;

Kloepfer, Pia ;

Bevan, Paul ;

Fall, Barbara ;

Wilhelm, Olaf ;

Stoerkel, Stephan ;

Said, Jonathan ;

Gambla, Michael ;

Hawkins, Robert E. ;

Jankilevich, Gustavo ;

Kapoor, Anil ;

Kopyltsov, Evgeny ;

Staehler, Michael ;

Taari, Kimmo ;

Wainstein, Alberto J. A. ;

Pantuck, Allan J. ;

Belldegrun, Arie S. .

JAMA ONCOLOGY, 2017, 3 (07) :913-920

← 1 2 3 4 5 6 7 8 9 10 →